DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy

Tiptiri-Kourpeti, Angeliki; Spyridopoulou, Katerina; Pappa, Aglaia; Chlichlia, Katerina

doi:10.1016/j.pharmthera.2016.05.004

Cited by 70 publications

(52 citation statements)

References 265 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an alternative to protein forms, antigens can be delivered as DNA or RNA, which are directly translated into the cytosol. This particular advantage has encouraged the development of DNA vaccines to enhance CTL responses (Tiptiri-Kourpeti et al, 2016).…”

Section: Post-targeting Fate Of Materialsmentioning

confidence: 99%

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Briquez

Hauert

Titta³

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Therapeutic cancer vaccines constitute a valuable tool to educate the immune system to fight tumors and prevent cancer relapse. Nevertheless, the number of cancer vaccines in the clinic remains very limited to date, highlighting the need for further technology development. Recently, cancer vaccines have been improved by the use of materials, which can strongly enhance their intrinsic properties and biodistribution profile. Moreover, vaccine efficacy and safety can be substantially modulated through selection of the site at which they are delivered, which fosters the engineering of materials capable of targeting cancer vaccines to specific relevant sites, such as within the tumor or within lymphoid organs, to further optimize their immunotherapeutic effects. In this review, we aim to give the reader an overview of principles and current strategies to engineer therapeutic cancer vaccines, with a particular focus on the use of sitespecific targeting materials. We will first recall the goal of therapeutic cancer vaccination and the type of immune responses sought upon vaccination, before detailing key components of cancer vaccines. We will then present how materials can be engineered to enhance the vaccine's pharmacokinetic and pharmacodynamic properties. Finally, we will discuss the rationale for site-specific targeting of cancer vaccines and provide examples of current targeting technologies.

show abstract

Section: Post-targeting Fate Of Materialsmentioning

confidence: 99%

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Briquez

Hauert

Titta³

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Another approach to potentiate anti-cancer immune response is the use of cancer vaccines, which provide the patient's immune system with specific tumor antigens. Therapeutic cancer vaccines can derive from whole tumor cells, protein antigens, peptides, DNA, or DCs (Figure 2) [92][93][94]. Whole-cell vaccines are able to induce an immune response against multiple tumor targets [94].…”

Section: Immunomodulatory Therapiesmentioning

confidence: 99%

“…Finally, active immunotherapies can also take advantage from the use of protein antigens, peptides and nucleic acids from tumor cells ( Figure 2) [92][93][94]. Several strategies for the delivery of genes encoding tumor antigens able to elicit a specific immune response have been described [92].…”

Section: Immunomodulatory Therapiesmentioning

confidence: 99%

“…Advancement for the implementation of delivery systems, development of adjuvants and other immune stimulatory signals, have led to the evaluation of DNA-based vaccines in clinical trials for different diseases, including breast cancer [92]. In addition, peptides derived from tumor-associated antigens, most of which are based on wild-type protein sequences overexpressed by cancer cells, can directly bind to HLA molecules, thus overcoming the need for antigen processing and presentation, and allowing an efficient activation of T cells [94].…”

Section: Immunomodulatory Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Progress in nonviral gene therapy for breast cancer and what comes next?

Bottai

Truffi

Corsi

et al. 2017

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

The possibility of correcting defective genes and modulating gene expression through gene therapy has emerged as a promising treatment strategy for breast cancer. Furthermore, the relevance of tumor immune microenvironment in supporting the oncogenic process has paved the way for novel immunomodulatory applications of gene therapy. Areas covered: In this review, the authors describe the most relevant delivery systems, focusing on nonviral vectors, along with the description of the major approaches used to modify target cells, including gene transfer, RNA interference (RNAi), and epigenetic regulation. Furthermore, they highlight innovative therapeutic strategies and the application of gene therapy in clinical trials for breast cancer. Expert opinion: Gene therapy has the potential to impact breast cancer research. Further efforts are required to increase the clinical application of RNAi-based therapeutics, especially in combination with conventional treatments. Innovative strategies, including genome editing and stem cell-based systems, may contribute to translate gene therapy into clinical practice. Immune-based approaches have emerged as an attractive therapeutic opportunity for selected breast cancer patients. However, several challenges need to be addressed before considering gene therapy as an actual option for the treatment of breast cancer.

show abstract

“…Суть данного подхода заключается в доставке гена, кодирующего целевой иммуноген, с помощью плазмидного или вирусного вектора в клетки, после чего в них происходит синтез соответствующего опухолевого белка-антигена, его процессинг с образованием отдельных пептидных фрагментов и представление их в комплексе с молекулами HLA I класса. Затем сформировавшиеся комплексы распознаются предшественниками CTL [26], что в конечном счете приводит к формированию специфических Т-клеток-эффекторов (CD8 + CTL), способных распознавать и уничтожать раковые клетки.…”

Section: пептидные вакциныunclassified

Untitled

2017

Biotehnologiâ (Mosk.)

View full text Add to dashboard Cite

Меланома -самый агрессивный рак кожи. Ежегодно от меланомы в мире умирают около 50 тыс. человек. Высокая смертность и низкая эффективность терапии данного заболевания связаны с метастазированием на ранних стадиях развития опухоли [1]. По данным ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, на долю меланомы приходится всего 4% злокачественных новообразований кожи, но до 80% летальных исходов среди всех видов рака кожи [2].В последние годы наметился существенный прогресс в области лечения рака с использованием различных методов терапии, на базе моно-клональных антител [3,4], низкомолекулярных ингибиторов белков BRAF и MEK [5-7], интерлейкинов, α-2b-интерферона, а также противоопухолевых вакцин [8,9].Использование противоопухолевых вакцин является одним из наиболее перспективных направлений развития иммунотерапии. Возможность создания эффективной терапевтической вакцины против меланомы обусловлена тем, что клетки меланомы, презентирующие на своей поверхности специфический набор антигенов, являются высоко иммуногенными. Кроме того, в пользу такой возможности свидетельствует и то, что в некоторых случаях наблюдается полная ремиссия Список сокращений: АПК − антиген-представляющие клетки; БЦЖ -бацилла Кальмета-Жерена; ГМ-КСФ -гранулоцитарно-макрофагальный колониестимулирующий фактор; ДК -дендритные клетки; CTL -цитотоксические Т-лимфоциты; FDA (Food and Drug Administration) − Управление по контролю за продуктами и лекарствами (США); HLA -главный комплекс гистосовместимости человека; IL -интерлейкин(ы); Th -Т-хелперы. Проблемы, перспективы

show abstract

DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy

Cited by 70 publications

References 265 publications

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Progress in nonviral gene therapy for breast cancer and what comes next?

Untitled

Contact Info

Product

Resources

About